• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis
【24h】

The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis

机译：米拉巴克对接受Tamsulosin疗法的良性前列腺增生诱导的过度活性膀胱的疗效和安全性：系统评价与荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: We conducted a meta-analysis to assess the efficacy and safety of mirabegron on overactive bladder (OAB) induced by benign prostatic hyperplasia (BPH) in men receiving tamsulosin therapy. Methods: We performed the analysis by using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The databases including MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were retrieved to get information regarding randomized controlled trials of mirabegron on OAB induced by BPH in men receiving tamsulosin therapy. We also searched the references of included literatures. Results: Three randomized controlled trials containing a total of 1317 BPH patients were included in the analysis. Co-primary efficacy end points: the mean number of micturitions per day [the mean difference (MD) = –0.27, 95% confidence interval (CI): –0.46 to –0.09, P = .004], the urgency episodes per day (the MD = –0.50, 95% CI: –0.77 to –0.22, P = .0004), the total OAB symptom score (the MD = –0.69, 95% CI: –1.00 to –0.38, P .0001), and mean volume voided (the MD = 10.76, 95% CI: 4.87–16.64, P = .0003) indicated that mirabegron was effective in treating OAB induced by BPH in men receiving tamsulosin therapy. Safety assessments that included treatment-emergent adverse events (odds ratio = 0.88, 95% CI: 0.68–1.13, P = .31) indicated that mirabegron was well tolerated with the exception of post-void residual urine volume (MD = 12.02, 95% CI: 6.01–18.04, P .0001). Conclusions: This analysis demonstrates that mirabegron is an effective and safe treatment for OAB symptoms induced by BPH in men receiving tamsulosin therapy with a low occurrence of side effects. Besides, we should be aware that the administration of mirabegron might have the risk of increasing post-void residual urine volume.
机译：背景：我们进行了一个荟萃分析，以评估M拉萨比克在接受甘草素治疗的男性良性前列腺增生（BPH）诱导的过度活性膀胱（OAB）上的疗效和安全性。方法：我们使用首选报告项目进行了系统评价和荟萃分析进行了分析。包括Medline，Embase和Cochrane受控试验登记册的数据库，以获取有关在接受Tamsulosin疗法的男性BPH诱导的OAB随机对照试验的信息。我们还搜索了包含文献的参考文献。结果：含有共1317氯患者的三项随机对照试验分析。共同初级疗效终点：每天的均值数目[平均差异（MD）= -0.27,95％置信区间（CI）：-0.46至-0.09，p = .004]，急流发作，每天的紧急事件（MD = -0.50,95％CI：-0.77至-0.22，p = .0004），总OAb症状分数（MD = -0.69,95％CI：-1.00至-0.38，P <.0001）并且平均体积无量值（MD = 10.76,95％CI：4.87-16.64，P = .0003）表明，Mirabegron有效地治疗BPH在接受Tamsulosin疗法的男性中诱导的OAB。包括治疗紧急不良事件的安全评估（差距= 0.88,95％CI：0.68-1.13，p = .31）表明，除了后空隙残留的尿量（MD = 12.02,95，M拉释聚苯耐受良好耐受性（MD = 12.02,95 ％ci：6.01-18.04，p <.0001）。结论：该分析表明，Mirabegron是对通过副作用的低发生的男性BPH引起的OAB症状的有效和安全的治疗方法。此外，我们应该意识到，Mirabegron的给药可能具有增加后残留尿量的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号